Hannah Chang is an investment director at Wu Capital. She focuses on early-stage biopharmaceutical investments out of the firm’s San Francisco office which she leads.
Representative investments include Semma Therapeutics (acquired by Vertex Pharmaceuticals), PACT Pharma, Perfuse Therapeutics, and Gemini Therapeutics. She was previously an investment professional at 5AM Ventures where she co-founded IDEAYA Biosciences (NASDAQ: IDYA) and served as a Board Observer for Crinetics Pharmaceuticals (NASDAQ: CRNX), Cleave Biosciences, Biodesy, and Ambrx. Earlier in her career Dr. Chang was a Project Leader at The Boston Consulting. Dr. Chang obtained her M.D. from Harvard Medical School, Ph.D. in Biophysics from Harvard University, and B.A. in Chemistry from Princeton University. She has published in the journals Nature, Lancet, and Physical Review Letters across a range of disciplines.
Dr. Chang obtained clinical training in internal medicine and ophthalmology at the Beth Israel Deaconess Medical Center and Massachusetts Eye and Ear Infirmary, respectively. She is a licensed internal medicine physician in the District of Columbia.